IL156361A0 - Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providing enhanced therapeutic activity - Google Patents

Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providing enhanced therapeutic activity

Info

Publication number
IL156361A0
IL156361A0 IL15636101A IL15636101A IL156361A0 IL 156361 A0 IL156361 A0 IL 156361A0 IL 15636101 A IL15636101 A IL 15636101A IL 15636101 A IL15636101 A IL 15636101A IL 156361 A0 IL156361 A0 IL 156361A0
Authority
IL
Israel
Prior art keywords
nsaids
therapeutic activity
enhanced therapeutic
protecting
gastrointestinal tract
Prior art date
Application number
IL15636101A
Other languages
English (en)
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of IL156361A0 publication Critical patent/IL156361A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15636101A 2000-12-19 2001-12-19 Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providing enhanced therapeutic activity IL156361A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25671100P 2000-12-19 2000-12-19
PCT/US2001/051605 WO2002085414A2 (en) 2000-12-19 2001-12-19 Nsaid formulations comprising lecithin oils for protecting the gastrointestinal tract and providing enhanced therapeutic activity

Publications (1)

Publication Number Publication Date
IL156361A0 true IL156361A0 (en) 2004-01-04

Family

ID=22973287

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15636101A IL156361A0 (en) 2000-12-19 2001-12-19 Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providing enhanced therapeutic activity
IL156361A IL156361A (en) 2000-12-19 2003-06-09 Non-aqueous NSAIDs with medical activity and containing a biocompatible lipid carrier that includes phospholipid for the protection of the stomach and intestinal system and methods for their preparation

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL156361A IL156361A (en) 2000-12-19 2003-06-09 Non-aqueous NSAIDs with medical activity and containing a biocompatible lipid carrier that includes phospholipid for the protection of the stomach and intestinal system and methods for their preparation

Country Status (18)

Country Link
EP (1) EP1343529B1 (es)
JP (2) JP4958381B2 (es)
KR (1) KR100884493B1 (es)
CN (2) CN102258457B (es)
AT (1) ATE414542T1 (es)
AU (1) AU2001297778B2 (es)
BR (1) BR0116380A (es)
CA (1) CA2431606C (es)
CY (1) CY1110474T1 (es)
DE (1) DE60136647D1 (es)
DK (1) DK1343529T3 (es)
ES (1) ES2317873T3 (es)
HK (1) HK1161107A1 (es)
IL (2) IL156361A0 (es)
MX (1) MXPA03005550A (es)
PT (1) PT1343529E (es)
SI (1) SI1343529T1 (es)
WO (1) WO2002085414A2 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060054405A (ko) * 2003-07-31 2006-05-22 더 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 암, 암의 발병 또는 암 증상의 치료, 예방 및/또는 개선용조성물 및 방법
US20050176809A1 (en) * 2004-02-05 2005-08-11 Rodlen Laboratories, Inc. Method and compositions for treatment of painful disorders
WO2005084683A1 (fr) * 2004-03-03 2005-09-15 MARTINS, José, Araujo Composition a base de lecithine vegetale, ex. de soja, vitamines du complexe b et d'acide acetylsalicylique, et son utilisation pour la fabrication d'un medicament pour le traitement des maladies neuro-degeneratives
CA2584505A1 (en) 2004-10-12 2006-04-27 Lenard M. Lichtenberger Purified phospholipid-non-steroidal anti-inflammatory drug associated compositions and methods for preparing and using same
GB0517673D0 (en) * 2005-08-31 2005-10-05 Astrazeneca Ab Formulation
CN101346128B (zh) * 2005-10-25 2013-10-02 雅培制药有限公司 包含低水溶解度药物的配方及其使用方法
KR20090034385A (ko) 2006-07-19 2009-04-07 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 염증성 장질환을 치료하기 위한 5-아미노살리실산 함유 약제 및 인지질의 제제
US20110008396A1 (en) * 2007-09-20 2011-01-13 Rutgers, The Sate University Of New Jersey Compositions and methods for treating cardiovascular conditions
GB2477590A (en) * 2010-02-05 2011-08-10 Biocopea Ltd A non-steroidal anti-inflammatory drug (NSAID) formulation comprising a lipid carrier
KR101957177B1 (ko) * 2010-10-22 2019-03-12 닥터 레디스 래보러토리즈 에스에이 상처를 치료하기 위한 저장 안정한 점성 인지질 데포의 용도
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
MX346224B (es) * 2011-02-04 2017-03-10 Biocopea Ltd Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias.
WO2013022410A2 (en) 2011-08-08 2013-02-14 Mahmut Bilgic Production method for effervescent formulations comprising dexketoprofen
KR102162901B1 (ko) * 2011-09-29 2020-10-08 피엘엑스 옵코 인코포레이티드 위장관을 따라 약물을 표적화 방출하기 위한 pH 감응성 담체, 그로부터의 조성물, 및 이들의 제조 및 사용 방법
EP2999487A1 (en) * 2013-05-23 2016-03-30 Neurosn, Inc. Diagnosing and treating alzheimer's disease using annexins with labeled with a radionuclide
RU2016136430A (ru) * 2014-02-11 2018-03-15 Др. Редди'С Лабораторис Лтд. Парентеральные композиции целекоксиба
CN103908454B (zh) * 2014-04-17 2016-08-24 兆科药业（广州）有限公司 一种药物组合物及其制备方法和应用
WO2016094617A1 (en) * 2014-12-11 2016-06-16 Phosphorex, Inc. Aqueous topical drug formulation with controlled release and increased stability
CN104739843A (zh) * 2015-04-15 2015-07-01 郭志标 一种用于治疗口腔溃疡的药物组合物
AU2019231699B2 (en) * 2018-03-07 2023-03-09 Andrew Xian Chen Aqueous formulations for insoluble drugs
CN108542909B (zh) * 2018-03-30 2020-07-07 浙江海昶生物医药技术有限公司 一种阿司匹林磷脂固化组合物、其制备方法及药物制剂
JP7229012B2 (ja) 2018-12-25 2023-02-27 小林製薬株式会社 内服用医薬組成物
AU2021244695A1 (en) 2020-03-26 2022-11-10 Plx Opco Inc. Pharmaceutical carriers capable of pH dependent reconstitution and methods for making and using same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60208910A (ja) * 1984-03-31 1985-10-21 Green Cross Corp:The 水難溶性薬物・リン脂質複合体の製造方法
US5154930A (en) * 1987-03-05 1992-10-13 The Liposome Company, Inc. Pharmacological agent-lipid solution preparation
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
AU661755B2 (en) * 1992-02-12 1995-08-03 Janssen - Cilag - S.p.a. Liposomal piroxicam formulations
JP3176425B2 (ja) * 1992-04-03 2001-06-18 三洋電機株式会社 空気調和機の電流検出方法および電流検出装置
ATE218872T1 (de) * 1995-01-27 2002-06-15 Univ Texas Verfahren zur erhöhung der therapeutischen wirkung von nsaids und dazu verwendbare zwitterionische phospholipidhaltige zusammensetungen
US5955451A (en) * 1995-05-12 1999-09-21 The University Of Texas System Board Of Regents Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein

Also Published As

Publication number Publication date
MXPA03005550A (es) 2004-05-14
CN102258457A (zh) 2011-11-30
BR0116380A (pt) 2005-04-05
DK1343529T3 (da) 2009-03-16
SI1343529T1 (sl) 2009-04-30
AU2001297778C1 (en) 2002-11-05
CN1543358A (zh) 2004-11-03
KR20030072565A (ko) 2003-09-15
JP2010031044A (ja) 2010-02-12
CA2431606C (en) 2011-07-19
EP1343529B1 (en) 2008-11-19
PT1343529E (pt) 2009-02-27
EP1343529A2 (en) 2003-09-17
WO2002085414A2 (en) 2002-10-31
KR100884493B1 (ko) 2009-02-18
IL156361A (en) 2011-04-28
ES2317873T3 (es) 2009-05-01
JP4958381B2 (ja) 2012-06-20
CN102258457B (zh) 2015-07-01
JP2005506303A (ja) 2005-03-03
CA2431606A1 (en) 2002-10-31
HK1161107A1 (en) 2012-08-24
WO2002085414A3 (en) 2003-05-08
DE60136647D1 (de) 2009-01-02
AU2001297778B2 (en) 2007-05-31
CY1110474T1 (el) 2015-04-29
ATE414542T1 (de) 2008-12-15

Similar Documents

Publication Publication Date Title
IL156361A0 (en) Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providing enhanced therapeutic activity
ES2605405T3 (es) Composiciones que contienen agentes antiacné y su uso
ES2260293T3 (es) Composicion que comprende acido hidroxicitrico y garcinol para reduccion de peso.
US9333185B2 (en) Topically administered strontium-containing complexes for treating pain, pruritis and inflammation
KR20110017451A (ko) 소염 진통 외용제
JP7322094B2 (ja) 疼痛、掻痒症および炎症のためのストロンチウムをベースとする組成物および製剤
EA200800056A1 (ru) Каннабиноидный активный фармацевтический ингредиент для лекарственных форм
KR20150129665A (ko) 심각한 통증 치료를 위한 조성물 및 방법
CA2264979A1 (fr) Composes bicycliques-aromatiques et leur utilisation en medecine humaine ou veterinaire ainsi qu'en cosmetologie
US20150010663A1 (en) Topically administered strontium-containing complexes for treating pain, pruritis and inflammation
WO2007014379A2 (en) A lipidic extract from lepidium meynii and its effect on the libido
US11235002B2 (en) Strontium based compositions and formulations for pain, pruritus, and inflammation
CA2334843A1 (fr) Composes diarylselenures et leur utilisation en medecine humaine ou veterinaire ainsi qu'en cosmetologie
US8975298B2 (en) Therapeutic agent for pain
CA2173172A1 (en) Petroleum jelly with inositol phosphates
ES2779525T3 (es) Composición que comprende un éster de alfa-tocoferol para prevención y tratamiento de rinitis alérgica
EP3284462A1 (en) Strontium based compositions and formulations for pain, pruritus, and inflammation
US20050042241A1 (en) Dr. Bob's Arthritis Cream
JPS6322518A (ja) Ｎ−（２，６−ジクロル−ｍ−トリル）アントラニル酸含有のゲル状製薬組成物
JP2019501221A (ja) 末梢関節、脊椎関節および／または結合組織の細胞外マトリックス構成要素の処置のための製剤、製造方法および使用
FR2860720A1 (fr) Nouvelles compositions pharmaceutiques pour traiter la xerostomie et maladies similaires
UA119715U (uk) Гель "апісан" для місцевої профілактики та лікування травматичних уражень слизової оболонки порожнини рота
WO2013167959A1 (en) Myrrh based composition for otological use
TH4847A3 (th) สารผสมทางเภสัชกรรมสำหรับบำบัดอาการปวด
TH4847C3 (th) สารผสมทางเภสัชกรรมสำหรับบำบัดอาการปวด